Comparative Pharmacology
Head-to-head clinical analysis: PEG LYTE versus PLENVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEG LYTE versus PLENVU.
PEG-LYTE vs PLENVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PEG-LYTE is an osmotic laxative that induces diarrhea by retaining water in the colon through the non-absorbable polyethylene glycol (PEG) and electrolytes, which prevent dehydration and electrolyte imbalance during bowel cleansing.
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
4 liters orally as a single dose or in divided doses for colonoscopy preparation.
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500mL, administered orally as a split-dose regimen: first dose (2 sachets in 500mL water) at 6-9 pm on the day before colonoscopy, followed by additional 500mL of clear fluids; second dose (2 sachets in 500mL water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500mL of clear fluids.
None Documented
None Documented
Not applicable; PEG-3350 is minimally absorbed (<0.06%), thus systemic half-life is not clinically relevant. Local gut transit time ~1-2 hours.
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Primarily fecal (98-99%) as unchanged polyethylene glycol (PEG) 3350; negligible renal excretion (<0.2%). Electrolytes (sodium, potassium, bicarbonate) are partially absorbed and excreted renally.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Category C
Category C
Osmotic Laxative
Osmotic Laxative